Categories
News

Multiple Sclerosis Drugs Market 2020-2026 Size, Share, Revenue, Global Research Report and Forecast

Pisco Market

A non-profit organization called Institute for Clinical and Economic Review (ICER) found that the U.S. spends around US$ 28,000 Mn every year for the treatment of multiple sclerosis. This will fuel demand for multiple sclerosis drugs, which will drive the global “Multiple Sclerosis Drugs Market”. The above information was shared by Fortune Business Insights in a report, titled “Multiple Sclerosis Drugs Market Size, Share and Global Trend By Drug Class (Immunomodulatory, Immunosuppressant, Interferons, Others), By Route of Administration (Oral, Injection), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Stores), and Geography Forecast till 2025.” Multiple sclerosis directly impacts the brain and spinal cord of a body. Consequently, multiple sclerosis symptoms include visual disturbances, memory and thinking problems, difficulties in coordination, and muscle weakness.

Request A Sample Copy – Multiple Sclerosis Drugs Market Report

Leading Players operating in the Multiple Sclerosis Drugs Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi

Mayzent’s FDA Approval Propels Growth of the Market

Several pharmaceuticals companies are undergoing clinical trials for the treatment of multiple sclerosis. Companies are putting efforts to develop innovative therapies in multiple sclerosis radiology for patients suffering from this disease. Considering this, Adamas Pharmaceuticals is undergoing phase 3 of a clinical trial on an investigational amantadine agent called ADS-5102. This oral therapy is conducted to determine if multiple sclerosis or MS patients can improve their walking speed. The U.S. FDA granted approval of a drug called Mayzent to Novartis. This is the first-ever treatment for patients suffering from secondary progressive multiple sclerosis or SPMS. Drugs like these will improve the patient’s quality of life, which will contribute to the growth of the market. 

View For More Details @ https://www.globenewswire.com/news-release/2019/07/19/1885221/0/en/Multiple-Sclerosis-Drugs-Market-to-Reach-US-39-289-5-Mn-by-2026-at-a-CAGR-of-6-7-Leading-Companies-Focus-on-Strategic-Collaborations-to-Expand-their-Footprint-says-Fortune-Business.html

Detailed Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities 
    • Market Trends
  • Key Insights
    • Prevalence of Multiple Sclerosis – For Key Countreis, 2018
    • Regulatory Scenario – For Key Countries
    • Patent Snapshot
    • New Drug Class Launch
    • Pipeline Analysis
    • Key Industry Developments – Mergers, Acquisitions and Partnerships
  • Global Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Drug Class
      • Immunomodulators
      • Immunosuppressants
      • Interferons
      • Others
    • Market Analysis, Insights and Forecast – By Route of Administration
      • Oral
      • Injection
        • Intramuscular
        • Subcutaneous
        • Intravenous
      • Market Analysis, Insights and Forecast – By Distribution Channel
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Stores
      • Market Analysis, Insights and Forecast – By Region
        • North America
        • Europe
        • Asia Pacific 
        • Latin America
        • Middle East & Africa
      • North America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2015-2026

Have Any Query? Ask Our Research Experts

Reasons to Purchase this Report:

  • Comprehensive analysis of the Multiple Sclerosis Drugs Market growth drivers, obstacles, opportunities, and other related challenges.
  • Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
  • Identifies market restraints and boosters.
  • Identifies all the possible segments present in the market to aid organizations in strategic business planning.

North America Generates the Maximum Revenue Owing to Rising FDA Approvals

North America is expected to dominate the global multiple sclerosis drugs market through the forecast years. Novel drugs manufactured are increasingly getting FDA approvals and these companies are planning to focus on commercialization of drugs. Influenced by this, the multiple sclerosis drugs market share is likely to expand in this region. Moreover, the region is worth US$ 13,826.7 Mn and owing to the mounting cost of drugs, the demand for multiple sclerosis treatment increases. Furthermore, the presence of potential drug candidates in North America is expected to create growth opportunities for the market during the forecast period.

Apart from North America, Europe is also anticipated to grow in the market owing to maximum support from government. Europe is the second-most leading region in the global market owing to rising per capita spending on healthcare.

More Trending Topics from Fortune Business Insights:

In vitro Diagnostics Market Trends, Size, Share, Industry Outlook, Sales Revenue, Global Regional Analysis by Key Players Forecast to 2026

Life Science Instrumentation Market 2020 Size, Share, Regional Growth, Industry Outlook and Forecast till 2026

Sexually Transmitted Diseases Testing Market Size, Growth 2020 Share, Merger, Leaders, Trends, Competitive Analysis and Forecast To 2026

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email:[email protected]

Linkedin | Twitter | BLogs

Categories
Press Release

Multiple Sclerosis Drugs Market: 2020 Global Size, Top Leading Countries, Companies, Drivers, Consumption, Trends, Revenue, Development Status, Forces Analysis, Challenges and Global Forecast 2026

Virtual Reality in Healthcare Market

The global multiple sclerosis drugs market is expected to gain from the development of economical therapy to treat multiple sclerosis (MS), finds Fortune Business Insights in a report, titled “MULTIPLE SCLEROSIS DRUGS: GLOBAL MARKET ANALYSIS, INSIGHTS AND FORECAST, 2019-2026.” According to the report, the global market was worth US$ 23,460.3 Mn in 2018. The market is anticipated to expand at a CAGR of 6.7% and reach US$ 39,289.5 Mn by the end of 2026.

The report offers a comprehensive overview of the global multiple sclerosis drugs market. The research report gives an entire study of the Multiple Sclerosis Drugs Market leaders with key statistics like sales, revenue, price, product picture and specifications, contact information, cost, capacity, production and company profile. The report offers critical information at the state of the enterprise. Marketing channels and development trends of the market is also well-found inside the report, making it a valuable source of information and path for agencies and individuals.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/multiple-sclerosis-drugs-market-100386

Development of New Therapeutics to Propel Growth

In terms of route of administration, the injection segment was leading the market in 2018 and is anticipated to expand considerably over the forecast period. The growth witnessed is attributable to the active government recommendation for the injection.

Development of new therapeutics for treating multiple sclerosis and rising awareness about the disease are a expected to drive the global multiple sclerosis drugs market. Additionally, increasing per-capita income and increasing healthcare expenditure are some factors anticipated to fuel the demand in the global market.

Leading Players operating in the Multiple Sclerosis Drugs Market are:

  • Biogen
  • Pfizer, Inc.
  • Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Other players

Tecfidera’s Increasing Sale to Drive Biogen’s Growth in Global Market

Biogen emerged as the leading player in the global multiple sclerosis market in 2018, owing to the high sales of Tecfidera. Biogen is expected to witness impressive growth during the forecast period gaining from strategical partnering with other players to widen the distribution network. Besides this, Novartis AG is also among the leading organizations. Owing to high demand for Gilenya, Novartis holds a strong position in the global market. In 2018, the National Institute for Health and Care Excellence announced to recommend Extavia among other beta interferon drugs such as Avonex, Betaferon and Rebif. This is anticipated to contribute towards Novartis’s market position. Further, this is anticipated to fuel the demand for multiple sclerosis treatment and drugs. Some of the companies operating in the global market are Pfizer, Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

View For More [email protected] https://www.globenewswire.com/news-release/2019/07/19/1885221/0/en/Multiple-Sclerosis-Drugs-Market-to-Reach-US-39-289-5-Mn-by-2026-at-a-CAGR-of-6-7-Leading-Companies-Focus-on-Strategic-Collaborations-to-Expand-their-Footprint-says-Fortune-Business.html

Segmentation of the Global Multiple Sclerosis Drugs Market:

By Drug Class

  • Immunomodulators
  • Immunosuppressants
  • Interferons
  • Others

By Route of Administration

  • Oral
  • Injection
    • Intramuscular
    • Subcutaneous
    • Intravenous

By Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores

By Geography

  • North America (USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Reasons to Purchase this Report:

  • Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
  • Comprehensive analysis of the Aesthetic Implants Market growth drivers, obstacles, opportunities, and other related challenges.
  • Identifies market restraints and boosters.
  • Identifies all the possible segments present in the market to aid organizations in strategic business planning.

Related Reports:

mHealth Marke Growth 2020 Industry Analysis by Size, Share, Industry Development, Overview and Forecast to 2026

Mobility Devices Market 2020 Global Industry Size, Top Key Companies, Industry Analysis by Growth, Future Trends | Regional Forecasts 2026

Contraceptives Market 2020 | Global Industry Size, Trends, Demand, Growth Factor and Forecast 2026

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email:[email protected]

Fortune Business Insights™

Linkedin | Twitter | BLogs

Categories
Press Release

Multiple Sclerosis Drugs Market Analysis by Trends, Size, Share, Company Overview, Growth and Forecast by 2026 | Latest Research Report Fortune Business Insights

Multiple Sclerosis Drugs MarketThe global multiple sclerosis drugs market to gain from development of economical therapy to treat multiple sclerosis (MS). Fortune Business Insights recently published a report, titled “Multiple Sclerosis Drugs: Global Market Analysis, Insights and Forecast, 2019-2026.” According to the report, the global market was worth US$ 23,460.3 Mn in 2018. The market is anticipated to expand at a CAGR of 6.7% and reach US$ 39,289.5 Mn by the end of 2026. The report offers a comprehensive overview of the global multiple sclerosis drugs market.

Request a Sample Copy of Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/multiple-sclerosis-drugs-market-100386

As per the report, North America emerged dominant in the global market in 2018. The region was valued at US$ 13,826.7 Mn in 2018. North America is anticipated to expand and continue dominate the market during the forecast period 2019-2026. The growth witnessed is attributable to the increasing demand and high price of multiple sclerosis drugs. Additionally, a lot key market players operate in the region and are expecting approval from the authority board for their newly developed therapeutics. This in response is expected to increase the growth rate in the global market. Europe is anticipated to stand second on the leading list by the end of 2026.

some of the key players in the global Multiple Sclerosis Drugs Market:

  • Pfizer, Inc.
  • Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386

The growth witnessed is attributable to increasing government spending and recommendations for multiple sclerosis treatment. This is expected to fuel the demand in the region. Besides this, Asia Pacific is anticipated to expand at the highest CAGR during the forecast period. Healthcare sector emerging in nations such as China and India is expected to contribute towards the Asia Pacific market expansion.

Tecfidera’s Increasing Sale to Drive Biogen’s Growth in Global Market

Biogen emerged as the leading player in the global multiple sclerosis market in 2018, owing to the high sales of Tecfidera. Biogen is expected to witness impressive growth during the forecast period by strategical partnering with other players to widen the distribution network. Besides this, Novartis AG is also among the leading organizations. Owing to high demand for Gilenya, Novartis holds a strong position in the global market. In 2018, the National Institute for Health and Care Excellence announced to recommend Extavia among other beta interferon drugs such as Avonex, Betaferon and Rebif. This is anticipated to contribute towards Novartis’s market position. Further, this is anticipated to fuel the demand for multiple sclerosis treatment and drugs. Some of the companies operating in the global market are Pfizer, Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

More Trending Topics from Fortune Business Insights:

Adult Malignant Glioma Therapeutics Market Size Worth US $2,964.5 Million at 9.3% CAGR Forecast till 2026

Blood Glucose Meters Market Share by Top Players to Worth USD 15.4 Billion by 2026 | Roche, Medtronic, Abbott, Sanofi and more

Dental Implants Market to Value US$ 5725.7 Mn at CAGR of 5.1% by 2026 | Exclusive Report by Fortune Business Insights

Ultrasound Equipment Market to Value US$ 10,500.8 Mn at CAGR of 5.1% by 2025 | Exclusive Report by Fortune Business Insights

About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Categories
Press Release

Multiple Sclerosis Drugs Market Size, Share, Trend and Global Analysis Forecast till 2026

The above information was shared by Fortune Business Insights in a report, titled “Multiple Sclerosis Drugs Market Size, Share and Global Trend by Drug Class (Immunomodulatory, Immunosuppressant, Interferons, Others), By Route of Administration (Oral, Injection), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Stores), and Geography Forecast till 2025.” Multiple sclerosis directly impacts the brain and spinal cord of a body. Consequently, multiple sclerosis symptoms include visual disturbances, memory and thinking problems, difficulties in coordination, and muscle weakness.

A non-profit organization called Institute for Clinical and Economic Review (ICER) found that the U.S. spends around US$ 28,000 Mn every year for the treatment of multiple sclerosis. This will fuel demand for multiple sclerosis drugs, which will drive the global multiple sclerosis drugs market.

Some of the major companies that are present in the Global Multiple Sclerosis Drugs Market are;

  • Biogen
  • Pfizer, Inc.
  • Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Other player

Get Sample PDF Brochure at https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/multiple-sclerosis-drugs-market-100386

As per a study conducted by the Multiple Sclerosis Foundation, around 2.3 million people across the world live with multiple sclerosis. Considering this, the report predicts the global market for multiple sclerosis drugs to expand at a CAGR of 6.7% between 2018 and 2026. Furthermore, the market was worth US$ 23,460.3 Mn in the year 2018 and is expected to reach US$ 39,289.5 Mn by 2026.

North America Generates the Maximum Revenue Owing to Rising FDA Approvals 

North America is expected to dominate the global multiple sclerosis drugs market through the forecast years. Novel drugs manufactured are increasingly getting FDA approvals and these companies are planning to focus on commercialization of drugs. Influenced by this, the multiple sclerosis drugs market share is likely to expand in this region. Moreover, the region is worth US$ 13,826.7 Mn and owing to the mounting cost of drugs, the demand for multiple sclerosis treatment increases. Furthermore, the presence of potential drug candidates in North America is expected to create growth opportunities for the market during the forecast period.

Apart from North America, Europe is also anticipated to grow in the market owing to maximum support from government. Europe is the second-most leading region in the global market owing to rising per capita spending on healthcare.

Improved distribution network among companies in Asia Pacific is the primary factor responsible for the market’s growth. The market is expected to witness high growth in this region during the forecast region.

Browse Complete Report Details at  https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386

Segmentation for Multiple Sclerosis Drugs Market

By Drug Class

  • Immunomodulators
  • Immunosuppressants
  • Interferons
  • Others

By Route of Administration

  • Oral
  • Injection
  • Intramuscular
  • Subcutaneous
  • Intravenous

By Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores

By Geography

Increasing R&D Activities Encourages Immunodulators to Lead

The multiple sclerosis drugs market share is expected to grow in the forecast years. Immunomodulators lead the market over immune suppressants and interferons. The segment covered a share of 67.4% in the global market in 2018.  The demand for immunomodulators is increasing as they offer better treatment options for multiple sclerosis. This, coupled with new product launches, is expected to drive the segment by 2026. This will further increase the multiple sclerosis drugs market. In addition to this, immunomodulators are growing rapidly owing to the increasing number of clinical studies and rising research and development (R&D) activities.

As per the route of administration, injection covered the maximum share in the global market in 2018. The wide market approvals and government support are driving the segment’s growth. However, the oral segment is expected to grow considerably in the forecast years.

Mayzent’s FDA Approval Propels Growth of the Market

Several pharmaceuticals companies are undergoing clinical trials for the treatment of multiple sclerosis. Companies are putting efforts to develop innovative therapies in multiple sclerosis radiology for patients suffering from this disease. Considering this, Adamas Pharmaceuticals is undergoing phase 3 of a clinical trial on an investigational amantadine agent called ADS-5102. This oral therapy is conducted to determine if multiple sclerosis or MS patients can improve their walking speed. The U.S. FDA granted approval of a drug called Mayzent to Novartis.

This is the first-ever treatment for patients suffering from secondary progressive multiple sclerosis or SPMS. Drugs like these will improve the patient’s quality of life, which will contribute to the growth of the market.

As per the report, Biogen, Novartis AG, and F. Hoffmann-La Roche Ltd cover the majority share in the global multiple sclerosis market. Among these, Biogen was the leading player owing to the increasing sales of Tecfidera in 2018. The company entered into strategic partnerships to further extend its distribution network. Following Biogen, Novartis is the second-most leading company in the market. The company developed a drug called Gilenya and owing to its higher demand, Novartis was leading after Biogen.

Check Discount at https://www.fortunebusinessinsights.com/enquiry/check-discount/multiple-sclerosis-drugs-market-100386

KEY QUESTIONS ANSWERED:

What is the market size and growth rate of the global and regional market by various segments?

What is the market size and growth rate of the market for selective countries?

Which region or sub-segment is expected to drive the market in the forecast period?

What Factors are estimated to drive and restrain the market growth?

What are the key technological and market trends shaping the market?

What are the key opportunities in the market?

What are the key companies operating in the market?

Which company accounted for the highest market share?

Why Choose Fortune Business Insights?

More Trending Topics from Fortune Business Insights:

North America Fats and Oils Market 2019 Industry Size by Global Major Companies Profile, Competitive Landscape and Key Regions 2026

Categories
Press Release

Multiple Sclerosis Drugs Market 2019 Size, Share and Global Trend Forecast till 2026

A non-profit organization called Institute for Clinical and Economic Review (ICER) found that the U.S. spends around US$ 28,000 Mn every year for the treatment of multiple sclerosis. This will fuel demand for multiple sclerosis drugs, which will drive the global multiple sclerosis drugs market.

The above information was shared by Fortune Business Insights in a report, titled “Multiple Sclerosis Drugs Market Size, Share and Global Trend by Drug Class (Immunomodulatory, Immunosuppressant, Interferons, Others), By Route of Administration (Oral, Injection), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Stores), and Geography Forecast till 2025.” Multiple sclerosis directly impacts the brain and spinal cord of a body. Consequently, multiple sclerosis symptoms include visual disturbances, memory and thinking problems, difficulties in coordination, and muscle weakness.

Get Sample PDF Brochure at https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/multiple-sclerosis-drugs-market-100386

Some of the major companies that are present in the Global Multiple Sclerosis Drugs Market are;

  • Biogen
  • Pfizer, Inc.
  • Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Other players

As per a study conducted by the Multiple Sclerosis Foundation, around 2.3 million people across the world live with multiple sclerosis. Considering this, the report predicts the global market for multiple sclerosis drugs to expand at a CAGR of 6.7% between 2018 and 2026. Furthermore, the market was worth US$ 23,460.3 Mn in the year 2018 and is expected to reach US$ 39,289.5 Mn by 2026.

North America Generates the Maximum Revenue Owing to Rising FDA Approvals 

North America is expected to dominate the global multiple sclerosis drugs market through the forecast years. Novel drugs manufactured are increasingly getting FDA approvals and these companies are planning to focus on commercialization of drugs. Influenced by this, the multiple sclerosis drugs market share is likely to expand in this region. Moreover, the region is worth US$ 13,826.7 Mn and owing to the mounting cost of drugs, the demand for multiple sclerosis treatment increases. Furthermore, the presence of potential drug candidates in North America is expected to create growth opportunities for the market during the forecast period.

Apart from North America, Europe is also anticipated to grow in the market owing to maximum support from government. Europe is the second-most leading region in the global market owing to rising per capita spending on healthcare.

Improved distribution network among companies in Asia Pacific is the primary factor responsible for the market’s growth. The market is expected to witness high growth in this region during the forecast region.

Browse Complete Report Details at  https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386

Segmentation for Multiple Sclerosis Drugs Market

By Drug Class

  • Immunomodulators
  • Immunosuppressants
  • Interferons
  • Others

By Route of Administration

  • Oral
  • Injection
  • Intramuscular
  • Subcutaneous
  • Intravenous

By Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores

By Geography

Increasing R&D Activities Encourages Immunodulators to Lead

The multiple sclerosis drugs market share is expected to grow in the forecast years. Immunomodulators lead the market over immune suppressants and interferons. The segment covered a share of 67.4% in the global market in 2018.  The demand for immunomodulators is increasing as they offer better treatment options for multiple sclerosis. This, coupled with new product launches, is expected to drive the segment by 2026. This will further increase the multiple sclerosis drugs market. In addition to this, immunomodulators are growing rapidly owing to the increasing number of clinical studies and rising research and development (R&D) activities.

As per the route of administration, injection covered the maximum share in the global market in 2018. The wide market approvals and government support are driving the segment’s growth. However, the oral segment is expected to grow considerably in the forecast years.

Mayzent’s FDA Approval Propels Growth of the Market

Several pharmaceuticals companies are undergoing clinical trials for the treatment of multiple sclerosis. Companies are putting efforts to develop innovative therapies in multiple sclerosis radiology for patients suffering from this disease. Considering this, Adamas Pharmaceuticals is undergoing phase 3 of a clinical trial on an investigational amantadine agent called ADS-5102. This oral therapy is conducted to determine if multiple sclerosis or MS patients can improve their walking speed. The U.S. FDA granted approval of a drug called Mayzent to Novartis.

This is the first-ever treatment for patients suffering from secondary progressive multiple sclerosis or SPMS. Drugs like these will improve the patient’s quality of life, which will contribute to the growth of the market.

As per the report, Biogen, Novartis AG, and F. Hoffmann-La Roche Ltd cover the majority share in the global multiple sclerosis market. Among these, Biogen was the leading player owing to the increasing sales of Tecfidera in 2018. The company entered into strategic partnerships to further extend its distribution network. Following Biogen, Novartis is the second-most leading company in the market. The company developed a drug called Gilenya and owing to its higher demand, Novartis was leading after Biogen.

Check Discount at https://www.fortunebusinessinsights.com/enquiry/check-discount/multiple-sclerosis-drugs-market-100386

KEY QUESTIONS ANSWERED:

What is the market size and growth rate of the global and regional market by various segments?

What is the market size and growth rate of the market for selective countries?

Which region or sub-segment is expected to drive the market in the forecast period?

What Factors are estimated to drive and restrain the market growth?

What are the key technological and market trends shaping the market?

What are the key opportunities in the market?

What are the key companies operating in the market?

Which company accounted for the highest market share?

Why Choose Fortune Business Insights?

More Trending Topics from Fortune Business Insights:

Categories
Press Release

Multiple Sclerosis Drugs Market 2019 Size, Share and Global Trend Forecast till 2026

A non-profit organization called Institute for Clinical and Economic Review (ICER) found that the U.S. spends around US$ 28,000 Mn every year for the treatment of multiple sclerosis. This will fuel demand for multiple sclerosis drugs, which will drive the global multiple sclerosis drugs market.

The above information was shared by Fortune Business Insights in a report, titled “Multiple Sclerosis Drugs Market Size, Share and Global Trend by Drug Class (Immunomodulatory, Immunosuppressant, Interferons, Others), By Route of Administration (Oral, Injection), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Stores), and Geography Forecast till 2025.” Multiple sclerosis directly impacts the brain and spinal cord of a body. Consequently, multiple sclerosis symptoms include visual disturbances, memory and thinking problems, difficulties in coordination, and muscle weakness.

Get Sample PDF Brochure at https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/multiple-sclerosis-drugs-market-100386

Some of the major companies that are present in the Global Multiple Sclerosis Drugs Market are;

  • Biogen
  • Pfizer, Inc.
  • Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Other players

As per a study conducted by the Multiple Sclerosis Foundation, around 2.3 million people across the world live with multiple sclerosis. Considering this, the report predicts the global market for multiple sclerosis drugs to expand at a CAGR of 6.7% between 2018 and 2026. Furthermore, the market was worth US$ 23,460.3 Mn in the year 2018 and is expected to reach US$ 39,289.5 Mn by 2026.

North America Generates the Maximum Revenue Owing to Rising FDA Approvals 

North America is expected to dominate the global multiple sclerosis drugs market through the forecast years. Novel drugs manufactured are increasingly getting FDA approvals and these companies are planning to focus on commercialization of drugs. Influenced by this, the multiple sclerosis drugs market share is likely to expand in this region. Moreover, the region is worth US$ 13,826.7 Mn and owing to the mounting cost of drugs, the demand for multiple sclerosis treatment increases. Furthermore, the presence of potential drug candidates in North America is expected to create growth opportunities for the market during the forecast period.

Apart from North America, Europe is also anticipated to grow in the market owing to maximum support from government. Europe is the second-most leading region in the global market owing to rising per capita spending on healthcare.

Improved distribution network among companies in Asia Pacific is the primary factor responsible for the market’s growth. The market is expected to witness high growth in this region during the forecast region.

Browse Complete Report Details at  https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386

Segmentation for Multiple Sclerosis Drugs Market

By Drug Class

  • Immunomodulators
  • Immunosuppressants
  • Interferons
  • Others

By Route of Administration

  • Oral
  • Injection
  • Intramuscular
  • Subcutaneous
  • Intravenous

By Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores

By Geography

Increasing R&D Activities Encourages Immunodulators to Lead

The multiple sclerosis drugs market share is expected to grow in the forecast years. Immunomodulators lead the market over immune suppressants and interferons. The segment covered a share of 67.4% in the global market in 2018.  The demand for immunomodulators is increasing as they offer better treatment options for multiple sclerosis. This, coupled with new product launches, is expected to drive the segment by 2026. This will further increase the multiple sclerosis drugs market. In addition to this, immunomodulators are growing rapidly owing to the increasing number of clinical studies and rising research and development (R&D) activities.

As per the route of administration, injection covered the maximum share in the global market in 2018. The wide market approvals and government support are driving the segment’s growth. However, the oral segment is expected to grow considerably in the forecast years.

Mayzent’s FDA Approval Propels Growth of the Market

Several pharmaceuticals companies are undergoing clinical trials for the treatment of multiple sclerosis. Companies are putting efforts to develop innovative therapies in multiple sclerosis radiology for patients suffering from this disease. Considering this, Adamas Pharmaceuticals is undergoing phase 3 of a clinical trial on an investigational amantadine agent called ADS-5102. This oral therapy is conducted to determine if multiple sclerosis or MS patients can improve their walking speed. The U.S. FDA granted approval of a drug called Mayzent to Novartis.

This is the first-ever treatment for patients suffering from secondary progressive multiple sclerosis or SPMS. Drugs like these will improve the patient’s quality of life, which will contribute to the growth of the market.

As per the report, Biogen, Novartis AG, and F. Hoffmann-La Roche Ltd cover the majority share in the global multiple sclerosis market. Among these, Biogen was the leading player owing to the increasing sales of Tecfidera in 2018. The company entered into strategic partnerships to further extend its distribution network. Following Biogen, Novartis is the second-most leading company in the market. The company developed a drug called Gilenya and owing to its higher demand, Novartis was leading after Biogen.

Check Discount at https://www.fortunebusinessinsights.com/enquiry/check-discount/multiple-sclerosis-drugs-market-100386

KEY QUESTIONS ANSWERED:

What is the market size and growth rate of the global and regional market by various segments?

What is the market size and growth rate of the market for selective countries?

Which region or sub-segment is expected to drive the market in the forecast period?

What Factors are estimated to drive and restrain the market growth?

What are the key technological and market trends shaping the market?

What are the key opportunities in the market?

What are the key companies operating in the market?

Which company accounted for the highest market share?

Why Choose Fortune Business Insights?

More Trending Topics from Fortune Business Insights:

Pelvic Organ Prolapse Repair Market Size 2019, Global Trends, Industry Share, Growth Drivers, Business Opportunities and Demand Forecast to 2026

Categories
Press Release

Multiple Sclerosis Drugs Market to Exhibit 6.7% CAGR, Leading Companies Focus on Strategic Collaborations to Expand their Footprint

The Global Multiple Sclerosis Drugs Market is expected to gain from the development of economical therapy to treat multiple sclerosis (MS), finds Fortune Business Insights in a report, titled “Multiple Sclerosis Drugs: Global Market Analysis, Insights and Forecast, 2019-2026.” According to the report, the global market was worth US$ 23,460.3 Mn in 2018. The market is anticipated to expand at a CAGR of 6.7% and reach US$ 39,289.5 Mn by the end of 2026. The report offers a comprehensive overview of the global multiple sclerosis drugs market.

Sample PDF Brochure  at https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/multiple-sclerosis-drugs-market-100386

Some of the major companies that are present in the Global Multiple Sclerosis Drugs Market are;

  • Biogen
  • Pfizer, Inc.
  • Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Other players

As per the report, North America emerged dominant in the global market in 2018. The regional market was valued at US$ 13,826.7 Mn in 2018. The North America market is anticipated to expand and continue to dominate the market during the forecast period 2019-2026. It is driven by the increasing demand for and high price of multiple sclerosis drugs. Additionally, several key market players operating in this region. Several among them are awaiting approval from the authorities for their newly developed therapeutics. This is expected to increase the growth rate in the global market. Europe is anticipated to stand second on the leading list by the end of 2026. The growth witnessed is attributable to increasing government spending and recommendations for multiple sclerosis treatment. This is expected to fuel the demand in the region. Besides this, Asia Pacific is anticipated to expand at the highest CAGR during the forecast period. Healthcare sector emerging in nations such as China and India is expected to contribute towards the Asia Pacific market expansion.

In 2018, Biogen collaborated with Eisai Co. Ltd. to promote Tecfidera, Tysabri, and Avonex in Japan. This is anticipated to increase the demand in the global market.

Development of New Therapeutics to Propel Growth

In terms of the route of administration, the injection segment was leading the market in 2018 and is anticipated to expand considerably over the forecast period. The growth witnessed is attributable to the active government recommendation for the injection.

Development of new therapeutics for treating multiple sclerosis and raising awareness about the disease is expected to drive the global Multiple Sclerosis Drugs Market. Additionally, increasing per-capita income and increasing healthcare expenditure are some factors anticipated to fuel the demand in the global market.

On the flip side, high cost associated with multiple sclerosis drugs and treatment and lack of availability of drugs are factors that may hamper the growth in the global market.

Major Table of Content Multiple Sclerosis Drugs Market are;

  1. Key Insights

4.1 Prevalence of Multiple Sclerosis – For Key Countries, 2018

4.2 Regulatory Scenario – For Key Countries

4.3 Patent Snapshot

4.4 New Drug Class Launch

4.5 Pipeline Analysis

4.6 Key Industry Developments – Mergers, Acquisitions and Partnerships

Tecfidera’s Increasing Sale to Drive Biogen’s Growth in the Global Market

Biogen emerged as the leading player in the global multiple sclerosis market in 2018, owing to the high sales of Tecfidera. Biogen is expected to witness impressive growth during the forecast period gaining from strategical partnering with other players to widen the distribution network. Besides this, Novartis AG is also among the leading organizations. Owing to the high demand for Gilenya, Novartis holds a strong position in the global market. In 2018, the National Institute for Health and Care Excellence announced to recommend Extavia among other beta interferon drugs such as Avonex, Betaferon and Rebif. This is anticipated to contribute towards Novartis’s market position. Further, this is anticipated to fuel the demand for multiple sclerosis treatment and drugs. Some of the companies operating in the global market are Pfizer, Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. 

View Related Report at

Non-Small Cell Lung Cancer Therapeutics Market to Expand Impressively CAGR, Increasing Demand for Early Cancer Detection to Enable Growth

Ultrasound Equipment Market to Expand at CAGR Canon’s ‘Aplio-a’ Series to Have a Positive Impact on Global Industry

About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.